Director, Global Health Outcomes, ViiV Healthcare

ViiV Healthcare•Durham, NC

4d•Hybrid

About The Position

The Director, Global Health Outcomes, joins ViiV Healthcare’s Global Health Outcomes function and leads the design and delivery of robust, decision-relevant evidence for an assigned portfolio of HIV treatment and prevention medicines, both in clinical development and on the market. The role shapes integrated health economics and outcomes research (HEOR) and value evidence strategies across real-world evidence (RWE), clinical outcome assessments (COAs), evidence synthesis and economic modelling. Working with research and development, medical affairs, market access, commercial teams and external stakeholders, the Director develops evidence plans that address decision-makers’ needs. The role sets a forward-looking COA and patient-centred outcomes strategy, embedding differentiated endpoints that demonstrate meaningful value to patients, clinicians, payers and healthcare systems. It ensures medicines are supported by scientifically credible, high-quality evidence that meets regulator, health technology assessment (HTA) body and payer requirements. Evidence generated informs product positioning, value propositions, value-based pricing, patient access, appropriate use and commercial success. The role requires strong scientific judgement and the ability to lead and influence in a complex matrix environment. The role reports to the Senior Director, Global Health Outcomes, ViiV Healthcare. The primary location is GSK London HQ, UK, with Durham, North Carolina, as a secondary location. Onsite presence is hybrid, and business travel is limited. People management is not involved.

Requirements

Advanced degree (Master’s or equivalent) in health outcomes, health economics, epidemiology, pharmacy, public health or a related discipline.
Significant pharmaceutical industry experience in health outcomes, real-world evidence, clinical outcome assessment strategies, market access or value evidence roles.
Demonstrated experience designing strategic evidence generation for reimbursement or HTA submissions and/or medical engagement across multiple markets.
Experience contributing to the development, validation or implementation of COA instruments or digital measures in clinical trials.
Knowledge of the diversity and complexity of healthcare markets, HTA agencies and reimbursement decision-making at global, regional and local levels.
Experience delivering studies and communicating findings in a complex, fast-paced matrix organisation.
Strong scientific judgement in study design, patient-reported outcomes and evidence synthesis.
Excellent communication and influencing skills, including the ability to translate data into strategic insights and business impact.

Nice To Haves

PhD or other advanced research degree in a relevant discipline.
Direct experience with global launches and above-country evidence strategy.
Experience leading COA instrument development or cross-cultural adaptation, from concept elicitation through psychometric validation.
Track record of peer-reviewed publications or scientific leadership.
Prior experience engaging with HTA agencies, guideline committees or payers.
Experience managing external vendors and large multi-country studies.
HEOR experience in HIV treatment and/or prevention, or in another chronic disease area with innovative or long-acting treatment options.
Methods expertise to deliver robust payer evidence and credibility engaging with external experts and leaders in the field.

Responsibilities

Define integrated evidence strategies for assigned assets, combining patient-focused outcomes, economic models and real-world evidence to meet regulatory, payer and other stakeholder needs.
Represent value evidence in cross-functional integrated evidence teams and decision forums, influencing asset decisions during development, launch and commercialization.
Define a Clinical Outcomes Assessment strategy for each asset, aligned with disease-area needs, regulatory expectations and payer evidence requirements.
Identify and integrate differentiated endpoints to strengthen asset value propositions.
Guide development and use of fit-for-purpose instruments and endpoint frameworks, supporting consistency and scalability across the HIV portfolio.
Partner with patient outcomes, clinical development, medical affairs and market access teams to translate strategy into study design, endpoints and evidence plans.
Engage payers, HTA bodies, guideline groups and academic partners to ensure evidence addresses decision-maker needs.
Oversee the quality, compliance, budget and delivery of health outcomes and real-world evidence studies, including pre-launch evidence generation and post-launch studies that sustain access and differentiation.
Build relationships with country, regional and global medical, market access, R&D and commercial teams, translating global evidence plans into local access and medical priorities.